Formoterol Via pMDI HFA-134a Propellant or DPI in Partially Reversible Chronic Obstructive Pulmonary Disease (COPD)
Double Blind, Double Dummy, Multicentre, Randomised, Placebo- Controlled, Crossover Design Clinical Trial of 12 μg (Single Dose and Repeated Doses) Formoterol Fumarate Administered Via pMDI With HFA-134a Propellant or DPI (Aerolizertm Inhaler) in Patients With Partially Reversible COPD
Sponsor: Cardarelli Hospital
This PHASE2 trial investigates Chronic Obstructive Pulmonary Disease and is currently completed. Cardarelli Hospital leads this study, which shows 5 recorded versions since 2004 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
5 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Aug 2020 — Jan 2021 [monthly]
Completed PHASE2
-
Jan 2017 — Aug 2020 [monthly]
Completed PHASE2
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cardarelli Hospital
- Carlo Mereu Struttura complessa di Pneumologia, S. Corona Hospital, Pietra Ligure (Savona), Italy
- Chiesi Farmaceutici S.p.A.
- Fondazione Don Carlo Gnocchi Onlus
- Giovanni Barisione Unità Operativa di Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria, S. Martino Hospital, Genoa, Italy
- Roberto Dal Negro Unità Operativa di Pneumologia, Hospital of Bussolengo (Verona), Italy
- Universita degli Studi di Genova
- University of Modena and Reggio Emilia
- University of Pisa
- Vito Brusasco Centro Dipartimentale di Fisiopatologia Respiratoria, University of Genoa, Italy (Co-ordinating centre)
For direct contact, visit the study record on ClinicalTrials.gov .